3 months to expiry Ghana · FDA Ghana

ZOLADEX 3.6MG INJECTION

CIOSERELIN

FDA/SD.233-050491 3.6

What it does

Cioserelin is a medication used to manage certain hormone-related conditions.

Commonly used for: prostate cancer, breast cancer, precocious puberty

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.233-050491
Registration date
2023-05-12
Expiry date
2026-07-01
Status
3 months to expiry
Active ingredient
CIOSERELIN
Dosage form
-
Strength
3.6
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Astrazeneca
Country of origin
-
Manufacturer location
Charter Way, Macclesfield SK10 2NA, UK

Source: Food and Drugs Authority · fetched 2026-04-18 08:37:09 · updated 2026-06-30 04:00:26

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Cioserelin is a medication used to manage certain hormone-related conditions.

What it treats

  • prostate cancer
  • breast cancer
  • precocious puberty

How it works

Cioserelin works by reducing the levels of certain hormones in the body, which can help slow down or stop the growth of hormone-sensitive cancers.

Who it's for

This medication is for adults with specific types of cancer and for children experiencing early puberty.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: cioserelin

Cioserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH) that functions primarily as an agonist. It is used to suppress gonadotropin secretion and is indicated for various hormone-sensitive conditions, particularly in the treatment of prostate cancer and certain gynecological disorders.

Indications

  • Prostate cancer
  • Endometriosis
  • Precocious puberty
  • Uterine fibroids

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Cioserelin acts on the pituitary gland to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) initially, but with continuous administration, it leads to downregulation of GnRH receptors. This results in decreased secretion of sex hormones such as testosterone and estrogen, effectively reducing their levels in the body.

Pharmacodynamics

The pharmacodynamic effects of cioserelin include suppression of the hypothalamic-pituitary-gonadal axis, leading to reduced circulating levels of sex hormones. This mechanism is beneficial in managing conditions that are hormone-dependent, such as advanced prostate cancer, endometriosis, and precocious puberty.

Pharmacokinetics

Cioserelin has a half-life of approximately 3 hours when administered subcutaneously. It is typically metabolized in the liver and excreted primarily in the urine. Its pharmacokinetic profile allows for once-daily or less frequent dosing depending on the clinical scenario, maintaining adequate suppression of hormone levels.

Contra-indications

  • Hypersensitivity to cioserelin or any of its components
  • Pregnancy
  • Severe hepatic impairment

Adverse effects

  • Hot flashes
  • Weight gain
  • Mood changes
  • Fatigue
  • Nausea
  • Injection site reactions
  • Bone pain
  • Decreased libido
  • Gynecomastia in males

Interactions

  • Caution with other drugs that affect hormonal levels
  • May interact with anticoagulants, increasing the risk of bleeding

Precautions

  • Monitor for signs of adrenal insufficiency
  • Assess for cardiovascular disease, as hormone therapy may increase cardiac risk
  • Use with caution in patients with osteoporosis

Pregnancy

Cioserelin is contraindicated in pregnancy due to potential harm to the fetus.

Breast-feeding

It is not known whether cioserelin is excreted in human milk. Caution should be exercised if administered to a nursing woman.

Storage

Store at 2 to 8 degrees Celsius. Protect from light. Do not freeze.

Formulations

  • Cioserelin acetate injectable solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.